NovMetaPharma Co (XKRX:229500) COGS-to-Revenue : 0.31 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co COGS-to-Revenue?

NovMetaPharma Co's Cost of Goods Sold for the six months ended in Dec. 2024 was ₩14.17 Mil. Its Revenue for the six months ended in Dec. 2024 was ₩45.32 Mil.

NovMetaPharma Co's COGS to Revenue for the six months ended in Dec. 2024 was 0.31.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NovMetaPharma Co's Gross Margin % for the six months ended in Dec. 2024 was 68.72%.

NovMetaPharma Co COGS-to-Revenue Historical Data

The historical data trend for NovMetaPharma Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co COGS-to-Revenue Chart

NovMetaPharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.83

0.50

0.49

0.46

0.31

NovMetaPharma Co Semi-Annual Data
	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial					0.83	0.50	0.49	0.46	0.31

NovMetaPharma Co COGS-to-Revenue Calculation

NovMetaPharma Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	14.174	/	45.315
	=	0.31

NovMetaPharma Co's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	14.174	/	45.315
	=	0.31

NovMetaPharma Co (XKRX:229500) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NovMetaPharma Co's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	14.174 / 45.315
	=	68.72 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NovMetaPharma Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NovMetaPharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR

Website

http://www.novmeta.com

NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines